Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 0.13
AUXL's Cash to Debt is ranked lower than
59% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.39 vs. AUXL: 0.13 )
AUXL' s 10-Year Cash to Debt Range
Min: 0.13   Max: 15218
Current: 0.13

0.13
15218
Equity to Asset 0.21
AUXL's Equity to Asset is ranked lower than
57% of the 712 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.60 vs. AUXL: 0.21 )
AUXL' s 10-Year Equity to Asset Range
Min: -1.32   Max: 0.61
Current: 0.21

-1.32
0.61
F-Score: 2
Z-Score: 0.45
M-Score: -0.90
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -16.99
AUXL's Operating margin (%) is ranked higher than
50% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.34 vs. AUXL: -16.99 )
AUXL' s 10-Year Operating margin (%) Range
Min: -335.41   Max: 21.62
Current: -16.99

-335.41
21.62
Net-margin (%) -4.51
AUXL's Net-margin (%) is ranked higher than
52% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.48 vs. AUXL: -4.51 )
AUXL' s 10-Year Net-margin (%) Range
Min: -327.31   Max: 21.74
Current: -4.51

-327.31
21.74
ROE (%) -7.18
AUXL's ROE (%) is ranked higher than
52% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. AUXL: -7.18 )
AUXL' s 10-Year ROE (%) Range
Min: -131.25   Max: 43
Current: -7.18

-131.25
43
ROA (%) -1.50
AUXL's ROA (%) is ranked higher than
55% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.94 vs. AUXL: -1.50 )
AUXL' s 10-Year ROA (%) Range
Min: -117.5   Max: 26.21
Current: -1.5

-117.5
26.21
ROC (Joel Greenblatt) (%) -193.04
AUXL's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 732 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.50 vs. AUXL: -193.04 )
AUXL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1109.08   Max: 292.53
Current: -193.04

-1109.08
292.53
Revenue Growth (%) 22.10
AUXL's Revenue Growth (%) is ranked higher than
87% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.10 vs. AUXL: 22.10 )
AUXL' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 28.7
Current: 22.1

0
28.7
EBITDA Growth (%) -36.80
AUXL's EBITDA Growth (%) is ranked lower than
54% of the 507 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. AUXL: -36.80 )
AUXL' s 10-Year EBITDA Growth (%) Range
Min: -68.8   Max: 75
Current: -36.8

-68.8
75
EPS Growth (%) -30.00
AUXL's EPS Growth (%) is ranked higher than
50% of the 510 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. AUXL: -30.00 )
AUXL' s 10-Year EPS Growth (%) Range
Min: -70.7   Max: 81.6
Current: -30

-70.7
81.6
» AUXL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

AUXL Guru Trades in Q1 2013

Steven Cohen 591,501 sh (+1485.62%)
Paul Tudor Jones 31,100 sh (+96.84%)
Columbia Wanger Sold Out
Chuck Royce Sold Out
Jim Simons 499,500 sh (-41.86%)
» More
Q2 2013

AUXL Guru Trades in Q2 2013

Jim Simons 928,200 sh (+85.83%)
Paul Tudor Jones 44,500 sh (+43.09%)
Steven Cohen 806,611 sh (+36.37%)
Stanley Druckenmiller Sold Out
» More
Q3 2013

AUXL Guru Trades in Q3 2013

Steven Cohen 1,136,631 sh (+40.91%)
Paul Tudor Jones 39,500 sh (-11.24%)
Jim Simons 238,500 sh (-74.31%)
» More
Q4 2013

AUXL Guru Trades in Q4 2013

Paul Tudor Jones 32,000 sh (-18.99%)
Jim Simons 115,900 sh (-51.4%)
Steven Cohen 423,581 sh (-62.73%)
» More
» Details

Insider Trades

Latest Guru Trades with AUXL

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2011-12-31 Sold Out 0.06%$14.21 - $19.93 $ 25.9756%0
George Soros 2011-09-30 New Buy0.06%$13.95 - $20.84 $ 25.9751%250000
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.12
AUXL's P/B is ranked lower than
53% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.84 vs. AUXL: 5.12 )
AUXL' s 10-Year P/B Range
Min: 1.85   Max: 67.57
Current: 5.12

1.85
67.57
P/S 3.20
AUXL's P/S is ranked higher than
50% of the 722 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. AUXL: 3.20 )
AUXL' s 10-Year P/S Range
Min: 0.45   Max: 15.15
Current: 3.2

0.45
15.15

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.71
AUXL's Price/Median PS Value is ranked higher than
88% of the 665 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.10 vs. AUXL: 0.71 )
AUXL' s 10-Year Price/Median PS Value Range
Min: 0.14   Max: 2.67
Current: 0.71

0.14
2.67
Earnings Yield (Greenblatt) 2.40
AUXL's Earnings Yield (Greenblatt) is ranked lower than
51% of the 595 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. AUXL: 2.40 )
AUXL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.6   Max: 30.9
Current: 2.4

2.6
30.9
Forward Rate of Return (Yacktman) -0.65
AUXL's Forward Rate of Return (Yacktman) is ranked higher than
67% of the 532 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.45 vs. AUXL: -0.65 )
AUXL' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -1.8   Max: -1.2
Current: -0.65

-1.8
-1.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:FEJ.Germany
Auxilium Pharmaceuticals, Inc. incorporated in the state of Delaware. The company is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences. It is currently market two products: Testim testosterone gel and XIAFLEX (collagenase clostridium histolyticum). Testim is a proprietary, topical 1% testosterone once-a-day gel indicated for the treatment of hypogonadism. Hypogonadism is defined as reduced or absent secretion of testosterone which can lead to symptoms such as low energy, loss of libido, and adverse changes in body composition, irritability and poor concentration. XIAFLEX is a proprietary, injectable collagenase enzyme approved by the United States ('U.S') Food and Drug Administration ('FDA') for the treatment of Dupuytren's contracture ('Dupuytren's') in adult patients with a palpable cord. Its current product pipeline includes: Phase III- XIAFLEX for the treatment of Peyronie's with top-line data expected late in the second quarter of 2012; Phase IIa: XIAFLEX for the treatment of Adhesive Capsulitis ('Frozen Shoulder syndrome') with top-line data expected in the first half of 2013; Phase Ib: XIAFLEX for the treatment of edematous fibrosclerotic panniculopathy ('cellulite') with top-line data expected in the fourth quarter of 2012. The company sells its products to wholesale drug distributors, specialty pharmacies, specialty distributors and chain drug stores who generally sell products to retail pharmacies, hospitals and other institutional customers. It is subject to various federal and state laws pertaining to health care fraud and abuse, including anti-kickback laws, false claims laws and physician self-referral laws.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide